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GVHD were marginally lower after HLA matched or mismatched
UCB transplants than after allele-matched BM. Notably, leuke-
mia-free survival (LFS) rates at 5 years were comparable between
those receiving allele matched BM (38%) and 1 locus high cell dose
(41%), 1 locus low cell dose (37%) or 2 loci (33%) HLA mis-
matched UCB. The observed higher LFS rate (60%) after HLA
matched UCB transplant requires validation in a larger cohort.
These results in LFS are in part explained by differences in risks of
transplant related mortality (TRM) and relapse between patient
populations. Compared to allele-matched BM transplants, TRM
was similar in recipients of matched and 1-locus mismatched UCB
and higher in recipients of 2-loci mismatched UCB. Conversely,
relapse rates were lower in recipients of UCB transplants mis-
matched at 2-HLA loci. These results are the ﬁrst to support the
use of HLA matched or mismatched UCB grafts with an adequate
cell dose as a ﬁrst line transplant treatment regardless of the
availability of a HLA allele-matched BM donor in the setting of
acute leukemia in children aged 16 years.
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INFLUENCE OF HLA DISPARITY AND GRAFT LYMPHOCYTES ON ALLO-
GENEIC ENGRAFTMENT AND SURVIVAL AFTER UMBILICAL CORD
BLOOD TRANSPLANT IN ADULTS
Willem J. van Heeckeren1, Laura R. Fanning1, Howard J. Meyerson2,
Pingfu Fu3, Hillard M. Lazarus1, Brenda W. Cooper1, Stanton L.
Gerson1, William W. Tse1, Tamila L. Kindwall-Keller1, Jennifer
Jaroscak4, Marcie Finney1, Robert N. Fox5, Luis Solchaga5, Margaret
Forster1, Richard J. Creger1, and Mary J. Laughlin1,2 1Department of:
Medicine, 2Pathology, 3Epidemiology and Biostatistics, 4Pediatrics, 5Case
Comprehensive Cancer Center, Case Western Reserve University, Cleve-
land, OH
Graft nucleated cell and CD34 hematopoietic progenitor cell
dose are predictors of allogeneic engraftment and survival in um-
bilical cord blood (UCB) recipients. In this single institution pro-
spective phase II trial, ﬂow cytometric analyses of CD34 progen-
itor and lymphocyte populations in unmodiﬁed single unit HLA-
disparate UCB grafts infused into 31 consecutive adults (median
age 41 years, range 20-64) receiving myeloablative conditioning
were compared with clinical outcomes. Median infused UCB graft
nucleated cells and CD34 dose was 2.2  107/kg and 1.2 
105/kg respectively. Day to absolute neutrophil count  500/L
with full donor chimerism averaged 27 days (range 12-41). Uni-
variate analyses demonstrated that UCB graft infused cell doses of
CD34 (p0.015), CD3 (p0.024) and CD34HLADR
CD38 progenitors (p0.043) correlated with neutrophil engraft-
ment. High-resolution matching for HLA-Class II (DRB1) re-
sulted in improved event-free survival (EFS) (p0.02) and de-
creased risk for acute graft versus host disease (GVHD) (p0.004).
Early mortality (prior to post-transplant day 28) occurred in
three patients, while twenty-six patients achieved myeloid engraft-
ment. These results suggest that UCB graft matching at DRB1 is
an important risk factor for acute GVHD and survival, while
higher UCB graft cell doses of CD34, committed CD34 pro-
genitors and CD3 T-cells favorably inﬂuence UCB allogeneic
engraftment.
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DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION AFTER MY-
ELOABLATION
John E. Wagner, M.D. and Claudio Brunstein, M.D. Blood and Mar-
row Transplant Program, University of Minnesota, Minneapolis, MN
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Cryopreserved umbilical cord blood (UCB) has been investigated
as a potential strategy for augmenting the pool of acceptable
donors, reducing the risks of acute and chronic graft-versus-host
disease (GVHD) and improving survival. Cell dose, however, has
clearly been identiﬁed as a major limitation, often preventing the
consideration of UCB for adult recipients. Recipients of 2.5 
107 nucleated cells/kg have slow hematopoietic recovery and sig-
niﬁcantly lower incidence of engraftment. Therefore, we explored
the potential of infusing two partially HLA matched units to
augment cell dose in patients who did not have an UCB graft
containing2.5 107 nucleated cells/kg. The underlying hypoth-
esis is that the addition of the second unit will enhance engraftment
and speed of hematopoietic recovery. One-hundred and twenty-
two patients [median age 23.2 years (range: 2.9-45.8); median
weight 64 kg (range: 12.6-148.6)] with high-risk hematologic ma-
lignancy were transplanted with a partially HLA-matched UCB
graft (70% received two units) after a single myeloablative condi-
tioning consisting of ﬂudarabine 75 mg/m2, cyclophosphamide 60
mg/kg and total body irradiation 1320 cGy. All received cyclospor-
ine and mycophenolate mofetil posttransplant immunoprophylaxis.
Patients had AML (n51), ALL (n46), CML (n10), MDS
(n4) or NHL (n11). The median total infused dose was 4.4 
107 NC/kg (range 1.1-13.9). The incidence of neutrophil recovery
was 91% (95% CI, 86-96) at a median of 23 days with no difference
observed in recipients of one or two units. Only CD34 cell dose
predicted incidence and speed of recovery. After engraftment, one
unit predominated in 90% with no factor (nucleated cell dose,
CD34 cell dose, HLA-match, ABO, sex, or order of infusion)
predicting which unit would predominate long term. Incidence of
grades II-IV and III-IV acute graft-versus-host disease (GVHD)
was 55% (95% CI, 44-66) and 17% (95% CI, 9-25) at day 100 with
an increased incidence of grade II disease only in recipients of two
units. Incidences of transplant-related mortality and relapse was
25% (95% CI, 17-33) at 1 year and 22% (95% CI, 12-32) at 2
years, respectively. Probabilities of overall and event-free survival
are 59% (95% CI, 49-69) and 51% (95% CI, 40-62) at 2 years,
respectively. Notably, recipients of two units had a trend toward
reduced relapse and improved event-free survival. These data sug-
gest that 1) double unit UCBT is safe with one unit predominating
over time, 2) double unit UCBT may extend the application of
UCB to nearly all adults and adolescents, and 3) double UCBT
may be associated with lower relapse and higher survival in those
with acute leukemia in complete remission. A NIH-CTN spon-
sored, multi-institutional randomized trial comparing outcomes in
recipients of single versus double UCB transplantation is open for
accrual.
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EFFECT OF CD26 ON CORD BLOOD, AND OTHER MEANS TO ENHANCE
ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS
Hal E. Broxmeyer, Ph.D. Indiana University School of Medicine, Indi-
anapolis, Indiana
A major goal of our laboratory and the focus of this presentation
is to enhance the efﬁciency of cord blood transplantation through
a better understanding of the mechanisms regulating hematopoi-
esis, and hematopoietic stem (HSC) and progenitor cell functions.
We have found that inhibition of CD26/Dipeptidylpeptidase IV
(DPPIV) with small peptides, such as Diprotin A (Ile-Pro-Ile) or
Val-Pyr enhance the capacity of human cord blood CD34 cells
and mouse Sca1c-kitLin bone marrow cells to respond to the
chemotactic activity of stromal cell derived factor (SDF-1/
CXCL12) in vitro (Christopherson, et al. J. Immunol 169:7000-
7008, 2002) and they enhance donor mouse bone marrow HSC
homing and engraftment of lethally irradiated recipient mice in
both a competitive and a non-competitive assay (Christopherson,
et al. Science 30:1000-1003, 2004). Enhanced engrafting capability
of gene transduced mouse bone marrow cells into lethally irradi-
ated mice (Tian, et al. Gene Therapy 13:652-658, 2006) and mouse
bone marrow cells in utero into mice (Peranteau, et al. Blood
108:4268-4274, 2006) has been noted by others in the context of
Diprotin A inhibition of CD26/DPPIV on donor cells. We now
report that inhibition of CD26/DPPIV in human cord blood
CD34 cells enhances their engraftment of non obese diabetic
(NOD)/Severe Combined Immunodeﬁcient (SCID) mice (Camp-
bell, et al. Stem Cells and Development [SCD], 16:347-353, 2007).
Others have seen Diprotin A enhancement of CD34 cord blood
(Christopherson, et al. SCD 16:355-360, 2007) and G-CSF mobi-
lized adult peripheral blood CD34 (Kawai, et al. SCD 16:361-
370, 2007) cells respectively by pretreating donor CD34 cells, or
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treating the recipient mice themselves. We have shown that pre-
treatment of lethally irradiated mice with Diprotin A enhances
engraftment of untreated donor mouse bone cells (Broxmeyer, et
al. N.Y. Acad. Sci. 1106:1-19, 2007). Future studies to enhance
HSC engraftment will encompass studies in higher animals and
human clinical trials. Also, modulation of the SDF-1/CXCL12-
CXCR4 axis may be useful for ex-vivo manipulation of donor cells
for engraftment.
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EXPANSION OF HUMAN UMBILICAL CORD BLOOD SCID-REPOPULAT-
ING CELLS USING CHROMATIN-MODIFYING AGENTS
Ronald Hoffman, MD Section of Hematology/Oncology, Department of
Medicine, University of Illinois at Chicago
We investigated whether the addition of two chromatin-modi-
fying agents, 5-aza-2’-deoxycytidine (5azaD) and trichostatin A
(TSA), to cord blood (CB) CD34() cells in culture results in
expansion of the numbers of severe combined immunodeﬁcient
(SCID) repopulating cells (SRC). Human CB CD34() cells were
cultured with cytokines in the presence or absence of 5azaD/TSA.
After 9 days of culture, the fold expansion of CD34() and
CD34()CD90() cell numbers, colony-forming unit (CFU)-mix,
cobblestone area-forming cell (CAFC), and SRC numbers were
determined. A 12.5-fold expansion of CD34()CD90() cells was
observed in the 5azaD/TSA-treated cultures in comparison to the
input cell numbers. Expansion of CD34()CD90() cells was
associated with a 9.8-fold increase in the numbers of CFU-mix and
11.5-fold increase in CAFC. 5azaD/TSA treatment of the CB
CD34() cells resulted in a 9.6-fold expansion of the absolute
number of SRC following 9 days of culture as determined by
limiting dilution analysis. Expansion of cells maintaining
CD34()CD90() phenotype was not due to the retention of a
quiescent population of cells because all of the CD34()CD90()
cells in the culture had undergone cellular division. 5azaD/TSA-
treated CD34()CD90() cells, but not CD34()CD90() cells
were responsible for in vivo hematopoietic repopulation potential
of nonobese diabetic/SCID mice. CONCLUSION: Ex vivo ex-
pansion strategy using chromatin-modifying agents provides a po-
tential avenue by which to expand the number of hematopoietic
stem cells (HSC) with a single CB unit for use as an alternative
source of HSC grafts for adult recipients.
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GLYCOGEN SYNTHASE KINASE-3 REGULATES EX-VIVO EXPANSION
AND ENGRAFTMENT OF UMBILICAL CORD BLOOD HEMATOPOIETIC
STEM CELLS THROUGH ACTIVATION OF WNT SIGNALLING
Tracey A. O’Brien, Tiffany Holmes and Alla Dolnikov Cord & Marrow
Transplant Facility, Centre for Children’s Cancer & Blood Disorders,
Sydney Children’s Hospital, Randwick, Sydney, Australia
Wnt signalling plays an important role in the regulation of
hematopoiesis. Previous murine experiments have demonstrated
activation of Wnt by different methodologies including use of
recombinant Wnt proteins, bone marrow stoma cells producing
Wnt proteins or by over-expression of constitutively active -cate-
nin gene, the main downstream effector of Wnt. Together these
studies provide evidence that Wnt signalling positively regulates
self-renewal of murine hematopoietic stem cells (HSCs). An alter-
nate approach to achieve Wnt activation is by inhibition of glyco-
gen synthase kinase-3 (GSK-3), which prevents degradation of
-catenin. We have explored the role of GSK-3 inhibition and
Wnt activation as a means to expand ex-vivo human umbilical cord
blood (UCB) cells. We have shown that GSK-3 inhibition sup-
presses ex-vivo proliferation of UCB cells induced by cytokines but
improves the repopulating capacity of UCB. Using a synthetic
GSK-3 inhibitor (6-bromoindirubin 3’-oxime; BIO) co-cultured
with UCB CD34 cells, we demonstrate that GSK-3 inhibition
suppresses ex-vivo expansion of committed HPCs while increasing
the pool of the most primitive progenitor/stem cells. UCB C34
cells cultured in BIO results in the accumulation of -catenin and
its re-location from the cytoplasm to the cell nucleus. In addition
up-regulation of c-myc and HoxB4 genes both known -catenin
targets involved in the regulation of stem cell renewal was ob-
served. GSK-3 inhibition also down-regulates cyclin D1 and
up-regulates p21Waf1 which may also account for reduced cell
cycling and maintenance of HSCs in BIO-treated UCB cells.
Additionally, GSK-3 inhibition increased CXCR4 expression and
adherence of UCB cells to stroma and reduced apoptosis in UCB
cells co-cultured with bone marrow stroma. Both delayed cell
cycling and reduced apoptosis may account for the increased out-
put of primitive progenitor/stem cells in BIO-treated UCB ob-
served in-vivo in the “humanised” NOD/SCID mouse model.
Using this model we have demonstrated both expansion and pres-
ervation of function with increased numbers of engrafting BIO
treated human CD34 UCB (120-fold expansion) compared to
control cells (45-fold expansion). In addition, increased output of
myeloid, lymphoid and megakaryocitic progenitor cells was ob-
served in NOD/SCID mice that received BIO-treated UCB cells.
The increased expansion of human NOD/SCID repopulating cells
suggests improved maintenance of stem cell function during ex-
vivo expansion of UCB in the presence of BIO. Signiﬁcantly higher
frequencies of SCID Repopulating Cells (SRC) were observed in
BIO-treated UCB cells by limiting dilution analysis. Increased
SRC numbers may result from the reduced apoptosis in BIO-
treated UCB cell cultures. The increased expression of CXCR4
resulting in the improved interaction of UCB cells with bone
marrow stroma, may also contribute to the increased SRC numbers
in BIO-treated UCB cells. In summary, using a humanized NOD/
SCID mouse model we have shown that activation of the Wnt
pathway through GSK-3 inhibition improves the repopulating
ability of human UCB hematopoietic progenitor/stem cells.
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DELTA1: A NOTCH UP ON CORD BLOOD TRANSPLANTATION?
Colleen Delaney, MD, MSC Fred Hutchinson Cancer Research Center,
Seattle, Washington
Current evidence indicates a role for Notch signaling in regulat-
ing cell-fate decisions of hematopoietic precursors. Earlier work
performed in our lab demonstrated enhanced self-renewal of re-
populating cells due to retrovirus-mediated expression of a consti-
tutively active form of Notch1. Subsequent studies demonstrated
that activation of endogenous Notch receptors by exogenously
presented Notch ligand was able to expand precursor cell numbers
from human and murine non-mutant stem cells, including those
with short-term and, in the case of human cells, possibly long-term
repopulating ability. Based on these ﬁndings, we have developed a
novel, Notch-ligand based, clinically relevant cGMP expansion
system for CD34 UCB progenitors, using an engineered form of
the Notch ligand, Delta1, consisting of the extracellular domain of
Delta1 fused to the Fc domain of human IgG1 (Delta1ext-IgG). In
this effort, we have demonstrated a relationship between Delta1ext-IgG
density and induced expression of the Notch target gene, Hes1,
and that ligand dose plays a critical role in determination of HSC
fate (Delaney et al, Blood, 106(8): 2693-9, Oct 2005). In pre-
clinical studies utilizing this system, culture of UCB progenitors
with Delta1ext-IgG signiﬁcantly enhanced the magnitude and kinet-
ics of marrow repopulation of immunodeﬁcient mice. Moreover,
limiting dilution assays demonstrated a 15.8 fold increase in re-
populating cell (SRC) frequency in Delta1-cultured cells compared
to non-cultured cells at 3 weeks (p0.0001) post infusion of cells
and a 6.3 fold increase in SRC frequency at 9 weeks (p0.0001),
indicating a signiﬁcant increase in repopulating ability after culture
with Delta1ext-IgG. Finally, important to the clinical objective of
overcoming the delayed engraftment associated with UCBT, the
kinetics of rapid early human engraftment were evaluated at 10
days in mice transplanted with Delta1-cultured cells as compared
to non-cultured cells. There was no measurable contribution to
engraftment 10 days post transplant in mice receiving non-cultured
cord blood cells, whereas the mice which received Delta1-cultured
cells resulted in all mice engrafting at a level of 0.5% human
engraftment. This data further suggests that culture with Delta1ext-IgG
dramatically enhances the early engraftment potential of cord
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